JAK2 and myeloproliferative disorder: Collectively, the clinical experience of JAK2 inhibitors, mostly with ruxolitinib, indicates that targeting JAK2 alone does not readily induce a reduction of MPN-driving allele burden suggesting this therapeutic treatment has little effect on disease-driving stem cells and is unlikely to induce remission.